Trial Condition(s):

Blood Loss, Surgical, Postoperative Hemorrhage

Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery

Bayer Identifier:

11799

ClinicalTrials.gov Identifier:

NCT00327379

EudraCT Number:

2005-003999-38

Terminated/Withdrawn

Trial Purpose

The objective of this study is to evaluate the safety and efficacy of aprotinin as compared to placebo, in reducing the need for blood transfusion in adult subjects undergoing elective spinal fusion surgery involving 3 to 7 vertebral levels with instrumentation

Inclusion Criteria
- Subjects requiring elective spinal fusion surgery involving 3 to 7 vertebral levels with instrumentation.  One vertebral level is defined as encompassing two vertebral bodies and one inter-vertebral disc space, so that a contiguous spinal fusion involving 3 vertebral levels would include 4 vertebral bodies and 3 inter-vertebral disc spaces.
Exclusion Criteria
- Subjects with previous exposure to aprotinin in the last 6 months.  If the subject has undergone cardiac surgery in the last 6 months, all attempts should be made to ascertain if aprotinin was administered during cardiac surgery.  If no records are available, or if the subject received aprotinin, the subject should be excluded.- Subjects with a known or suspected allergy to aprotinin.
 - Subjects with sepsis or a known bone infection.- Subjects with known bone malignancy.
 - Subjects with a creatinine clearance less than 30mL/min as calculated by the Cockcroft-Gault formula.  
 - Subjects with a history of bleeding diathesis or known coagulation factor deficiency.
 - Subjects with failure of a major organ system or any active significant medical illness that in the opinion of the Investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study
 - Subjects who refuse to receive allogenic blood products for religious or other reasons.
 - Subjects whose preoperative red blood cell volume is so low that a blood transfusion would be likely to be given perioperatively (preoperative hematocrit or hemoglobin values <24% or <8 g/dl, respectively).
 - Subjects who have participated in an investigational drug study within the past 30 days
 - Subjects with a history of deep vein thrombosis or pulmonary embolism.
 - Subjects who are pregnant or breast feeding.
 - Women of childbearing potential in whom the possibility of pregnancy cannot be excluded by a negative serum pregnancy test at screening.
 - Women of childbearing potential who are not using a reliable method of contraception.  
 - Planned use of other antifibrinolytic agents.
 - Subjects on chronic anticoagulant treatment with Vit K antagonists that cannot be temporarily discontinued for the surgical procedure (as per local practices).

Trial Summary

Enrollment Goal
54
Trial Dates
black-arrow
Phase
3
Could I receive a placebo?
Yes
Products
Trasylol (Aprotinin, BAYA0128)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Berlin, Germany, 13086

Status
Completed
 
Locations

Investigative Site

Barcelona, Spain, 08035

Status
Completed
 
Locations

Investigative Site

Barcelona, Spain, 08036

Status
Completed
 
Locations

Investigative Site

Windsor, Canada, N9A 1E1

Status
Completed
 
Locations

Investigative Site

Montreal, Canada, H3A 2B4

Status
Completed
 
Locations

Investigative Site

Berlin, Germany, 13353

Status
Completed
 
Locations

Investigative Site

Karlsbad, Germany, 76307

Status
Completed
 
Locations

Investigative Site

Münster, Germany, 48149

Status
Completed
 
Locations

Investigative Site

Neustadt, Germany, 23730

Status
Completed
 
Locations

Investigative Site

Barcelona, Spain, 08003

Status
Completed
 
Locations

Investigative Site

Valencia, Spain, 46010

Status
Completed
 
Locations

Investigative Site

Madrid, Spain, 28034

Status
Completed
 
Locations

Investigative Site

Pamplona, Spain, 31008

Status
Completed
 
Locations

Investigative Site

Oshawa, Canada, L1G 2B9

Status
Completed
 

Trial Design